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ABSTRACT 
Hepatitis C virus (HCV) infection post-liver transplantation (post-LT) is associated with an 
increased rate of fibrosis progression compared to non-transplanted patients. Thus, 25% of 
the recipients will progress to cirrhosis within 5 years after LT. Antiviral treatment after LT 
with peg-INF and ribavirin (RBV) yields lower sustained viral response (SVR) than in non-
transplanted patients. In many LT-recipients non-response to treatment will eventually lead to 
progression to cirrhosis.  
The aim of this thesis was to study the natural course and treatment outcome in liver 
transplant patients with hepatitis C recurrence, and the influence of baseline factors on the 
course of the HCV recurrence and antiviral treatment, with particular emphasis on HCV 
genotype and IL28B gene polymorphism.  
In paper I we conducted a pilot-study on 21 hepatitis C LT recipients with the aim to 
increase adherence and tolerance to antiviral treatment. All recipients were pre-treated with 
Darbepoetin (EPO) starting 2 weeks before the initiation of Peg-IFN and RBV. RBV was 
dosed taking weight and kidney function into account, with a target serum concentration set 
to10 µM/L by using a formula to calculate the dose.  A majority of patients achieved the 
target concentration, and 90% could stay adherent to a full treatment course. SVR was 
reached in 18% recipients with genotype 1 and 60% with genotype non-1. Recipients with 
mild fibrosis achieved SVR in 67%. In paper II we studied the influence of IL28B gene 
polymorphism on fibrosis progression and treatment outcome in 54 LT recipients, who had 
received antiviral treatment, and in 45 of their donors. The most favorable IL28B genotype 
CC was associated with slower fibrosis progression and better treatment outcome. Patients 
with HCV genotype non-1 and the IL28B CC gene achieved SVR in 71%, whereas patients 
with genotype 1 and IL28B non-CC did so in only 23%, p < 0,016. Patients with mild fibrosis 
(F1-2) had better treatment outcome than patients with advanced fibrosis. In paper III we 
treated 46 Swedish and 8 Norwegian patients with the treatment regimen evaluated in paper I. 
94% stayed adherent to the treatment course. SVR was achieved in 82% of recipients with 
HCV genotype 2/3 versus in only 22% with genotype 1, p < 0.002. Patients with IL28B CC 
achieved SVR in 73% and patients with non-CC in 33%, p < 0.001. Patients with mild 
fibrosis achieved SVR in 56% and patients with advanced fibrosis in 26% p < 0.01. Thus, 
with favorable HCV genotype and IL28B genotype, LT recipients have a good chance to 
achieve SVR, when treated before advanced fibrosis has developed. In paper IV we 
evaluated the utility of an early liver biopsy post-LT to detect and predict fibrosis progression 
of recurrent HCV infection post-LT. 35 HCV RNA positive, and 11 HCV RNA negative LT 
recipients, who underwent protocolled liver biopsies 6 and 12 months post-LT, were studied. 
Histological recurrence with fibrosis stage ≥ F1was noted in 56% of the HCV positive LT 
recipients at 6 months, and in 82% 12 months post-LT. Acute cellular rejection (ACR) and 
IL28B genotype CC were associated with a more pronounced fibrosis progression 12 months 
post-LT. Fibrosis was absent in all eleven recipients who were HCV RNA negative directly 
after LT. Thus, a 6 months biopsy post-LT is a valuable tool for detection of an early HCV 
recurrence, which makes an early treatment intervention for HCV possible. 
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ALT alanine aminotransferase 
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INTRODUCTION HEPATITIS C 
1.1 HISTORY 
 
In the 1950s and 1960s the field of viral hepatitis evolved from the observations of so 
called serum-hepatitis (1), later proven to be caused by  infections with hepatitis A virus 
(HAV) and hepatitis B virus (HBV) (2). In the mid-1970s , when serological tests were 
introduced, analysis of earlier stored sera from transfusion studies made it clear that 
neither of these known viruses caused the majority of blood-transmitted hepatitis cases 
(3). This unknown hepatitis, with slowly progressing fibrosis, was named non-A, non-B 
(NANB) hepatitis. When the genome of NANB virus was characterized in 1989 (4), it 
showed similarities with Flavivirus ( flaviviridae), and was named hepatitis C virus 
(HCV). An assay was developed to detect antibodies, anti-HCV (5) , and general blood 
donor screening became possible in the early 90s. 
 
1.2   VIROLOGY AND GENOTYPES 
 
 
 
 Figure 1: Structure of Hepatitis C virus  
 
HCV is a single-stranded RNA virus and the genome consists of approximately 9 600 
nucleotides which encodes a single glycoprotein cleaved into three structural proteins and seven 
non-structural proteins (6).  The virus replicates rapidly in the cytoplasm of the hepatocytes and 
because the HCV RNA polymerase lacks proofreading, multiple quasispecies are generated and 
circulate simultaneously (7).  
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HCV is divided in seven major genotypes (8), and each genotype in several subtypes with 
varied global distribution. HCV genotypes 1-4 are most common. In Sweden, genotype 1a and 
3a are most common, approximately 30% each, followed by genotype 2 with about 20% (9). 
 
1.3   EPIDEMIOLOGY 
 
HCV is endemic in most parts of the world, with an estimated 180 million people being infected 
worldwide, comprising about 3% of the global population (10, 11). Some 350 000 persons die 
each year from HCV related liver disease. The highest prevalence, 5-10%, has been reported 
from Africa and the Middle East (12), in Egypt as high as 12.5% due to iatrogenic spread during 
Schistosomiasis treatment campaigns (13). In the majority of developed countries the 
prevalence is below 2%. 
In Sweden the prevalence of anti-HCV positive individuals is approximately 0.6%, whereof 
77% have a chronic hepatitis C (14, 15). Hence, there are approximately 55 000 individuals 
infected with HCV in Sweden, and the annual rate of newly diagnosed individuals some 1500. 
The majority of the HCV infected individuals in Sweden are born in the 1950s and 1960s, and 
probably became infected in the 1970s and 1980s, when IVDU started to become more widely 
spread among the young population (16).  
The transmission route is parenteral exposure, including transfusions before blood screening 
became mandatory in the early 90s, injections, household exposures and perinatal transmission 
(17). IVDU is the main route of transmission in the Western Countries. The risk of transmission 
by an infected needle has been calculated to 1.8 %, and in Stockholm more than 80% of PWID 
(people who inject drugs) are anti-HCV positive (18). In the recently initiated needle exchange 
program in Stockholm, 83% of the individuals in the program were anti HCV positive, and 74% 
of these also HCV RNA positive. (M Kåberg, personal communication). The sexual 
transmission rate in heterosexual couples is low (1.5%). Among MSM (men who have sex with 
men) the rate is dependent on sexual practices which lead to transmission of blood, the viral 
load, use of intravenous drugs, and concomitant STIs (sexually transmitted infections) (19). 
In Sweden the incidence of co-infection with HIV is low. Only 7% of the HIV infected cohort is 
co-infected with HCV according to the national InfCare HIV register (15)(Stenkvist et al 2014 
in press)  
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1.4   THE NATURAL COURSE OF HEPATITIS C INFECTION 
 
 
 
Figure 2: The Natural course of Hepatitis C infection 
 
Only some 20% of HCV infected individuals will develop symptoms of acute hepatitis with 
jaundice, malaise and anorexia 1-3 months after being infected. The majority, will have an 
asymptomatic disease. The chance to achieve a spontaneous clearance is approximately 25%, 
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hence 75% will go on to develop chronic HCV and risk HCV-related end stage complications, 
such as liver cirrhosis and hepatocellular carcinoma (HCC). Approximately 10 -15 % will 
eventually develop cirrhosis over 20 years, which in turn carries a 2-4% yearly risk for HCC. 
Factors associated with a risk to develop chronic HCV infection are age > 25 years at the time 
of infection, male gender, asymptomatic disease during the acute infection, IL28B genotype 
non-CC, HIV co-infection and immunosuppression (20, 21). 
1.4.1   Factors influencing the natural course 
Generally, hepatitis C progresses slowly over 20-25 years, then turning into a more rapid 
progression. The course, however, is highly variable, and efforts have been made to identify risk 
factors associated with a more rapid fibrosis progression. A major risk factor for progression to 
cirrhosis is alcohol. Further risk factors include older age at time of infection, male gender, 
IL28B non-CC, higher degree of inflammation and fibrosis present, co-infection with human 
immunodeficiency virus (HIV) or hepatitis B virus (HBV), all factors that is associated with a 
more rapid progression of fibrosis. HCV genotype, on the other hand, does not seem to be 
associated with fibrosis progression. (20, 22, 23).  
1.5   DETECTION OF HCV RELATED FIBROSIS AND CIRRHOSIS 
Scarring of the liver, evaluated as fibrosis stage, is a slowly evolving process during a chronic 
HCV infection progressing towards cirrhosis. Evaluation of the extent of fibrosis and its 
progression is thus very important. 
1.5.1   Liver biopsy  
Liver biopsy has been the gold standard for grading and staging the liver disease. In mild cases, 
fibrosis is limited to the portal tracts, whereas more advanced fibrosis extends from one portal 
area to another, also known as "bridging fibrosis”. In cirrhosis, nodules of liver parenchyma are 
formed surrounded by fibrotic tissue. The inflammatory activity is graded based on the extent of 
inflammation. It is evaluated by the amount of inflammatory cells present in the border of the 
portal tract causing cell death, also named “interface activity”. One of the few validated scoring 
systems used for classification of fibrosis in HCV patients is the METAVIR scoring system 
(24). The fibrosis stage is divided in four levels, F0-F4, ranging from F0, absence of fibrosis, to 
F4 corresponding to cirrhosis. The necro-inflammatory activity is classified in four levels, A0 – 
A3, where A0 means no inflammatory activity and A3 corresponds to severe activity. At 
Karolinska University Hospital the liver biopsies are evaluated according to Batts and Ludwig, 
a scoring system similar to METAVIR, where fibrosis stage is divided into F0-F4 and 
inflammatory activity is classified into five levels, A0-A5 (25).  
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1.5.2   Liver stiffness measurement by transient elastography (TE) 
In recent years, liver biopsy has gradually been replaced by non-invasive methods, such as 
transient elastography (TE), a non-invasive method measuring the liver stiffness in kilo Pascal 
(kPa) (FibroScan®, Echosens, Paris, France) (26). Measuring liver elasticity with TE has 
demonstrated a high accuracy to detect advanced fibrosis where a cut-off of more than 9,5 kPa 
is used to define advanced fibrosis (≥ F3)  
1.6 ANTIVIRAL TREATMENT IN HCV INFECTED NON-
TRANSPLANT PATIENTS  
The main goal with treatment is viral eradication, leading to stabilization and improvement of 
liver function, and a diminished risk to develop end-stage liver complications and hepatocellular 
carcinoma (HCC). 
1.6.1   Treatment regimens 
In the mid 1980´reports on treatment for non-A, non-B hepatitis with IFN were published (27). 
In the late 1990´the addition of RBV was found to improve the outcome when combined with 
IFN, mainly by reducing the rate of relapses after treatment (28-31). The addition of a 
polyethyleneglycol molecule to interferon (Peg-IFN) renders IFN a longer half-life, allowing 
once-weekly dosing, with more stable IFN serum levels over time, resulting in a higher 
response rate of 50-80% depending on genotype (32, 33). Today with the recent development of 
direct acting antivirals (DAA) for treatment of chronic HCV infection, IFN based treatment will 
be replaced with IFN-free treatment options with shorter treatment courses and higher efficacy 
(34-40). 
1.6.2   Predictors of treatment response 
Patient related predictors of response to IFN-based therapy are age, sex, pre-treatment HCV 
RNA levels and fibrosis stage, and the most important are HCV genotype and IL28B gene 
polymorphism (41, 42). Furthermore, on-treatment predictors of response, in particular early 
virological response (EVR), is highly predictive of SVR, as is adherence to the antiviral 
treatment, both dosing and treatment length (43, 44). 
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2 LIVER TRANSPLANTATION IN HCV INFECTED 
PATIENTS 
2.1   HISTORY 
The first liver transplantation was performed in the 1960s. Hereafter, the surgical technique, 
immune-suppressive regimens, patient selection criteria, organ allocation, and the organ 
preservation techniques have undergone great improvement and refinement, resulting in better 
graft and patient survival (45). The indication for LT is mainly end-stage liver disease and 
HCC, when other therapies have failed or are judged to be inferior. Presently, the leading 
indication for LT in the Western world is cirrhosis caused by chronic hepatitis C (46).  
2.2   IMMUNOSUPPRESSION  
Immunosuppression (IS) after LT is necessary to prevent allograft rejection and is generally 
life-long. In a few recipients, however, complete withdrawal of IS has been possible (47). In 
general, during the IS induction phase, peri-operatively and early post-LT, when the risk of 
ACR is highest, high dose of IS is given. The IS dose is hereafter gradually tapered and finally 
given as lower doses in the maintenance phase, generally reached after some months post liver 
transplantation.  
2.2.1   General principles in immunosuppression 
Most regimens use Calcineurin inhibitors (CNI), either cyclosporine A (CyA) or Tacrolimus, as 
the major agents for maintenance IS. An antimetabolite, mainly Mycophenolate (MMF), is 
added to reduce the doses of CNI, in order to minimize the side-effects induced by CNI, mainly 
nephrotoxicity, diabetes mellitus and de-novo tumours, and some centers also use low dose 
steroids (48,49). 
2.2.2   Immunosuppression in HCV infected recipients 
In liver transplant recipients with HCV, there is no consensus regarding the optimal IS regimen. 
The strategy is to avoid over-immunosuppression and unnecessary use of steroid boluses, and 
slowly taper the IS doses, since high, or rapidly changing, doses of corticosteroids is associated 
with increased replication of HCV RNA and fibrosis progression (50, 51). Steroid-sparing 
regimens have been investigated with no clear benefit regarding patient and graft survival or 
ACR, but some centers prefer a steroid-sparing regimen to minimize co-morbidities associated 
with steroids, mainly diabetes mellitus, obesity and osteoporosis (52-54). 
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3 HCV RECURRENCE  
3.1   KINETICS  
Hepatitis C recurrence occur very early post-transplant, in fact, already during the reperfusion 
phase. By day 4 after transplantation, serum HCV RNA levels reach pre-transplant levels (55). 
The viral load increases over the following weeks to levels higher than in non-transplant 
patients, reaching a plateau 1-2 logs higher than pre-LT levels at approximately 1 month post-
transplant (56). 
3.2   MECHANISM  
The proposed mechanism causing allograft injury in the liver during recurrent HCV infection is 
thought, at least in part, to be caused by the increased hepatitis C viral load which appears to 
overcome the inhibitory effect on the immune system caused by the immunosuppression. This 
results in an enhanced inflammatory response and an induction of antiviral interferon inducible 
genes leading to an HCV-driven enhanced proliferation, apoptosis and fibrosis response in the 
allograft (57). 
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3.3   THE NATURAL COURSE OF FIBROSIS PROGRESSION 
   
 
 
Figure 3: Natural course of HCV recurrence after liver transplantation 
Biochemically and histologically, acute hepatitis after transplantation is usually detected 
between 1 and 3 months post-transplant (58). However, the course can be highly variable as 
chronic hepatitis develops either as a typical chronic hepatitis with late-onset fibrosis 
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progression, or as a more aggressive, sometimes severe cholestatic form (57, 59, 60). The most 
aggressive form causes fibrotic cholestatic hepatitis (FCH), which is a severe, rapidly 
progressive liver injury seen in < 10% of liver transplant patients (61). FCH is associated with 
high HCV RNA levels, jaundice and biochemical cholestasis. It is more often seen in patients 
who have received high doses of immunosuppression early post-transplant, including pulses of 
methylprednisolone or anti-lymphocyte therapy used for ACR episodes. Therefore, treatment of 
mild rejection with steroid boluses should be used cautiously, and mild rejections should rather 
be treated with increased dosing of the baseline IS drugs (62). 
3.3.1   Fibrosis progression rate 
Overall, the rate of fibrosis progression is accelerated in liver transplant recipients compared to 
what is observed in immune competent hosts. Thus, liver transplant recipients with hepatitis C 
relapse will develop cirrhosis in 20-40% within 5 years after transplantation (58, 63). Repeated 
biopsies have demonstrated an annual rate of fibrosis progression between 0.3-0.6 stages/year 
staged by the Metavir system, compared to only 0.1-0.2 stages/year in immune competent 
patients with hepatitis C (22, 64, 65). Hence, the median interval from transplantation to 
development of cirrhosis is 9.5 years versus 30 years in liver transplant recipients and non-
transplanted immune competent hosts, respectively.  
Once cirrhosis has developed the 1-year risk to develop hepatic decompensation is 
approximately 40% in immune competent patient, which is increased to more than 70% in liver 
transplant patients with established cirrhosis (66, 67, 68). Thus, identification of patients at risk 
to develop severe HCV recurrence after liver transplantation at an early stage, to be able to 
provide treatment, is very important.  
3.3.2   Long-term survival 
In several studies, graft and patient survival post-LT in HCV positive recipients are significantly 
lower than in LT recipients without HCV (63, 64, 69). Patient and graft survival rates have 
improved steadily in HCV negative recipients, however, the same trend is not seen in HCV 
positive patients (70, 71). Hence, the 5-year survival rate in HCV positive LT recipients is 60-
65% as compared to 75% in HCV negative recipients with even lower survival rates seen in 
HCV infected recipients with concomitant HCC (63, 64, 69). In the Scandinavian registry, the 
5-year survival rate in HCV positive recipients was 71% in recipients without HCC versus 46 % 
in recipients with HCC (69). This illustrates that HCV infection with HCC is associated with 
the least favorable survival rates. Older donors and donor liver histology, with findings of 
steatosis in the graft, has also been associated with lower patient and graft survival (69, 72, 73). 
3.3.3   Graft survival 
The graft survival in HCV positive LT recipients is impaired compared to that in LT recipients 
without HCV. The 5-year survival rate in HCV positive LT recipients is 55 % compared to 67-
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71 % in LT recipients without HCV (63, 69). In re-transplanted LT recipients with HCV, the 
donor age is associated with an increased rate of graft failure (64). 
3.4   DETECTION OF HCV RECURRENCE 
3.4.1   Liver biopsy early post-transplant  
A liver biopsy performed early (0-3 months) post-LT, often due to elevated liver enzymes 
and/or bilirubin, can be very difficult to evaluate. It is important to determinate whether 
recurrent HCV or rejection is the cause of the allograft dysfunction, or other causes. HCV is an 
uncommon cause of dysfunction during the initial months after liver transplantation, although 
occasional cases of severe acute HCV occurs early post-LT. In contrast, most acute rejection 
(ACR) episodes occur within the first 30 days (74, 75). It is of great importance to discriminate 
between ACR and HCV recurrence, since treatment for ACR with steroid bolus doses, or anti-
lymphocyte therapy with OKT-3, is associated with a more rapid fibrosis progression (71, 76, 
77).  
3.4.2   Protocolled liver biopsy 
Several studies have shown an association between early hepatitis C recurrence and disease 
progression. Hence, the activity and fibrosis extent observed in the biopsy taken 12 months after 
transplantation was found to be associated with the progression of fibrosis and survival (59, 60, 
65). Thus, only 3-10% with mild fibrosis 1-year after transplantation will progress to cirrhosis, 
as opposed to 30-60% of recipients who have developed severe fibrosis. It was suggested that a 
1-year biopsy would have the best ability to identify recipients with an increased risk to have a 
rapid fibrosis progression.  
At Karolinska University Hospital, protocolled liver biopsies are performed already at 6 months 
post-LT, and hereafter continuously on a yearly basis, with the aim to detect HCV recurrence as 
early as possible. 
Repeated liver biopsies, however, carries a risk, although small, for severe complications. 
Furthermore, they are suffering from sample variability and are not preferred by the patients 
(78). Hence, non-invasive methods for evaluation of fibrosis stage are preferred by most 
patients. 
3.4.3   Liver stiffness measurement (LSM) 
LSM is a non-invasive alternative to liver biopsy post-LT, described in detail in Methods. It is 
found to have a diagnostic accuracy for detection of significant fibrosis and cirrhosis, and to 
predict the clinical outcome post-LT (79-81). At 12 months post-LT, evaluation with LSM is 
useful for discrimination of recipients who will have rapid versus slow fibrosis progression, in 
particular if combined with clinical variables (82). In a recent review, a liver elasticity cut-off 
 11 
 
value at 8.7 kPa was identified, which delineates significant fibrosis and cirrhosis (F3-4) (83). 
This cut-off level is now recommended and has a sensitivity and negative predictive value for 
detection of significant fibrosis of > 0.90. Early post-LT, however, several confounding factors 
are operating which have a great influence on the kPa value, such as ischemia, acute cellular 
reaction, toxic reactions to immune suppressive drugs. 
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4   FACTORS ASSOCIATED WITH THE COURSE OF HCV     
RECURRENCE 
In the transplant setting, many factors will have an impact on the disease progression. Efforts 
have been made to pinpoint the patients who will have the highest risk to develop a rapid and 
aggressive fibrosis progression post-LT. 
4.1   VIRAL FACTORS 
4.1.1   HCV viral load and genotype 
A high pre-transplant viral load (>10 x 6 IU/mL) is associated with an increased risk for fibrosis 
progression, graft loss, and mortality (71, 84). The significance of the HCV genotype is more 
controversial, but genotype 1, and in particular 1b, have been thought to be involved with a 
more rapid fibrosis progression, and higher risk to develop cirrhosis (59, 85).  
4.1.2   Cytomegalovirus 
Recurrence of cytomegalovirus (CMV) post-transplant has been associated with a more rapid 
fibrosis progression (86), probably due to high levels of immunosuppression. However, today, 
with highly effective prophylaxis regimens and surveillance with monitoring of CMV DNA 
serum levels, the impact of recurrent CMV on fibrosis progression in HCV recurrence has been 
reduced to a minimum. 
4.1.3   HIV co-infection 
Co-infection with HIV in transplant recipients is associated with a more aggressive and rapid 
fibrosis progression and a higher rate of severe HCV recurrence such as FCH, resulting in lower 
survival rates compared to recipients without HIV infection (87). The mechanisms are not fully 
understood. Treatment with ART (anti-retroviral therapy) for HIV seems to slow down the 
fibrosis progression. Hence, it is recommended that ART should be initiated early in co-infected 
patients (EACS guidelines 2013, www.eacsociety.org). 
4.2 DONOR AND RECIPIENT-RELATED FACTORS   
Several donor and recipient factors have been evaluated regarding the fibrosis progression in 
recipients with HCV recurrence after liver transplantation. Evaluating donor factors may help us 
to understand the mechanisms leading to more severe recurrent hepatitis C, and possibly to 
predict the clinical and histological outcome of hepatitis C in the graft recipients. 
4.2.1   Donor and recipient age     
In some studies it has been shown that older donor age affects the rate of fibrosis progression 
and patient survival, although the results are not uniform. A 10-year difference in donor age (40 
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vs 50 years) was associated with an increase in the fibrosis progression rate from 0.6 to 2.1 
units/year, and donor age >33 years was independently associated with cirrhosis in recurrent 
HCV in another study (59, 88). A Swedish study showed a significant reduction in patient 
survival with older donor age (>60 years), whereas the graft survival was associated with the 
presence of inflammation in the donor graft (73). An increased rate in fibrosis progression post-
transplant have been noted, and that progression was independently associated with the year of 
transplantation, the same group concluded that the increasing donor age, seen over time, due to 
shortage of organs, is believed to be one contributing factor to the decrease in survival among 
liver transplanted patients with HCV (71, 72). These findings contributed to the discussion 
whether allocating younger donor grafts should be done or not to HCV recipients.  
The association between older recipient age and fibrosis progression is not firmly established. 
Thus, some authors have claimed that older recipients receiving grafts from older donors have 
both lower long-time graft and patient survival than older recipients receiving grafts from 
younger donors (89). This suggests that using older donors for older recipients should be 
avoided. 
4.2.2   Liver graft steatosis 
The influence of steatosis in the liver graft on long-term survival has yielded conflicting results 
from different groups. Some suggests that donor steatosis will lead to a more rapid fibrosis 
progression, whereas others fail to see this association (90-93). 
4.2.3   IL28B gene polymorphism in donor and recipient 
The impact of IL28B genotype on fibrosis progression in recipients with HCV recurrence after 
liver transplantation, both in the donor and recipient, is under current investigation. The IL28B 
genotype, however, has a great influence on the spontaneous clearance of an acute hepatitis C 
and on the treatment response in non-transplant patients (21, 42). The IL28B genotype also 
seems to play an important role for liver transplant recipients with recurrent HCV for prediction 
of disease progression. The IL28B genotype both in donor and recipient seem to be equally 
important to study. The results so far have been inconsistent, especially concerning the donor 
genotype, and further studies are needed. Regarding IL28B in the recipient, the IL28B genotype 
TT seems to be correlated with a more rapid recurrence, whereas genotype CC seems to be 
associated with a more slow progression of fibrosis post-transplant (23, 94-96). The results 
regarding the donor IL28B genotype, however, are not conclusive. Two different groups have 
stated that IL28B CC in the donor seems to be associated with a more rapid course of HCV 
recurrence indicated by higher ALT and HCV RNA levels post-transplant, and an earlier 
recurrence of hepatitis in the liver (96, 97). All studies so far have failed to show a clear survival 
benefit induced by the favorable IL28B genotype both in the donor and recipient. However, the 
IL28B CC genotype is associated with higher SVR rates in liver transplant recipients treated 
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with peg-IFN and ribavirin, where the response to treatment leads to higher long-term survival 
rates (94, 98) 
4.3   IMMUNOSUPPRESSION 
The extent of the immunosuppression used is correlated to the progression of hepatitis C after 
liver transplantation. This is at least in part due to the increase in viral load which it causes. It 
seems that high levels of immune suppression, and in particular sudden changes in the IS drug 
dosing, is detrimental and causes accelerated progression of the liver injury. Hence, a delicate 
balance exists between the risk for ACR with appropriate dosing of the IS drugs and the risk for 
accelerated HCV progression with over-immunosuppression.  
 4.3.1   Steroids 
Steroid boluses are given early post-transplant to prevent ACR, but boluses used to treat ACR 
are associated with a more severe course of the HCV recurrence (71, 84), and induce higher 
HCV RNA levels and shorten the time to HCV recurrence. However, the strategy of rapid and 
early steroid withdrawal may also lead to an increase in the rate of fibrosis progression, possibly 
causing an immunological rebound (57), and improvement in outcome is shown if rapid steroid 
tapering is avoided (50). This led to the recommendations not to change the level of 
immunosuppression rapidly, and not to use over-immunosuppression, and only give steroid 
pulses to liver transplant recipients with HCV when a severe ACR is properly diagnosed. 
4.3.2   Calcineurin inhibitors 
The possible different impact on HCV recurrence between cyclosporine (CyA) and tacrolimus 
(TAC) is controversial. In in vitro studies, CyA is found to suppress hepatitis C replication (99, 
100) This, however, has not resulted a better outcome in CyA treated recipients with HCV 
recurrence. In a prospective, randomized study on 122 liver transplant recipients there was no 
significant difference in the rate of severe HCV recurrence one year post-LT or in the survival 
rate (101). 
4.4   RISK FACTORS ASSOCIATED WITH DEVELOPMENT OF 
CIRRHOSIS 
If advanced fibrosis is present already 12 months post-LT, the risk of rapid fibrosis progression 
to HCV-related graft cirrhosis is considerable (59, 65, 76). Treatment for ACR with boluses of 
methylprednisolone or anti-lymphocyte therapy, which increases the fibrosis progression post-
LT, is also found to be associated with a higher risk of cirrhosis development post-LT. 
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4.5   RE-TRANSPLANTATION IN PATIENTS WITH HCV 
RECURRENCE 
Re-transplantation (re-LT) is the only therapeutic option when decompensated liver disease due 
to HCV recurrence has developed after primary LT. However, re-LT due to HCV recurrence is 
controversial, because of its increased rate of graft loss and high patient mortality rates (102). 
The main reason for re-LT within the first 14 days after the primary transplantation is non-
function in the graft, followed by vascular thrombosis, whereas HCV recurrence only accounts 
for 0.5%. The indication for re-LT caused by HCV recurrence increase to 5.3% between day 15 
and 222, to 24.5% between day 223 and 1307, and to 20.2% after day 1308 post-LT. Thus, 
recurrent HCV is a leading cause for re-transplantation. 
The one-year patient survival after re-transplantation due to HCV recurrence in the graft 
amounts to some 70%, whereas the outcome in HCV negative recipients undergoing re-LT is 
steadily improving and much better (70). Graft and patient survival is found to be significantly 
lower in HCV infected recipients as compared to HCV-negative patients who underwent re-LT 
after within 90 days after the primary LT (103).  
The best approach to prevent re-LT in recipients with HCV recurrence is antiviral treatment, 
which can eradicate HCV and stabilize fibrosis progression. Up till today, IFN-based therapy 
was the only option. With the introduction of direct acting antivirals (DAAs), it is now possible 
to treat patients with HCV recurrence easier and safer both prior to and after transplantation 
with highly improved SVR rates (104, 105). 
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5 ANTIVIRAL TREATMENT WITH PEG-IFN AND RBV IN 
LIVER TRANSPLANT PATIENTS WITH HCV 
RECURRENCE 
5.1   INTRODUCTION 
Due to the often severe impact HCV recurrence has on the graft and patient survival, causing 
cirrhosis in 30% of the recipients within 5 years, treatment for hepatitis C recurrence is 
important to improve the outcome post-LT (63, 66). Several treatment strategies have been 
evaluated both pre- and post-LT. In general, antiviral therapy with peg-IFN and RBV is less 
effective in transplant recipients than in non-transplant patients, and the tolerability less good.  
Initial studies based on IFN mono-therapy yielded poor results, with very low SVR rates (106). 
The addition of RBV improved SVR rates somewhat to reach 20% (107). With the introduction 
of peg-IFN in combination with RBV, viral clearance rates improved to 26%-45%. In a review 
from 2008, the average SVR rate in 19 evaluated studies was 30% (108-110). The low response 
rate is partly explained by the large proportion of HCV genotype 1 patients, premature 
discontinuation of therapy due to side-effects, and the high proportion of patients with advanced 
fibrosis and cirrhosis. In recent years, the impact of a non-favorable IL28B genotype is also 
found to be a contributing factor, since an accumulation of the unfavorable IL28B genotype 
non-CC is found in HCV infected liver transplanted recipients (94, 97). Although treatment 
results have clearly improved during recent years with peg-IFN and ribavirin, the side-effects 
are still a major limitation.  
In order to optimize treatment response and minimize side-effects, the most important aspects to 
study have been timing of the initiation of antiviral therapy, optimal dosing of Peg-IFN and 
RBV, whether to use growth factors or not, and how to diminish the risk for allograft rejection. 
5.2   TIMING OF TREATMENT 
5.2.1   Treatment prior to transplantation 
Antiviral therapy administered before transplantation, in order to clear the infection pre-
transplant, with the aim of preventing recurrence, is attractive. However, treatment with Peg-
IFN and RBV during 24-28 weeks has not been successful, due to the frequent adverse events 
causing many withdrawals and serious complications including deaths. The alternative is a 
shorter course leading to an “on-treatment” negative serum HCV RNA at time of 
transplantation. Studies have shown that HCV recurrence was prevented in all patients who 
achieved SVR before transplantation. The SVR rate, however, was low, approximately 20% 
(111, 112), and the treatment caused many side-effects and life-threatening complications, 
including infection and decompensation (113). The virological response with the shorter 
treatment pre-transplant was 30 %, however, due to HCV persistence in peripheral mononuclear 
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cells, the SVR rate dropped to 20% (114). In practice, treatment prior to transplantation with 
Peg-IFN and RBV is only feasible in patients with Child-Pugh A cirrhosis, making this strategy 
applicable in only some 50% of the patients.  
5.2.2   Treatment after transplantation 
The main goal in treating liver transplant recipients with HCV recurrence is clearance of HCV. 
The stabilization, or even improvement, of fibrosis seen after a successful treatment is also a 
reason to offer antiviral therapy.  The treating physician has to balance the efficacy against the 
tolerability before a treatment decision is taken, in order to maximize the usefulness of 
treatment. A major challenge when treating HCV-infected transplant recipients is to improve 
SVR rates and minimize side effects. For this, timing of treatment initiation and dosing is 
important to study.  
5.2.3   Pre-emptive treatment 
Pre-emptive treatment has been used very early after transplantation, before recurrent hepatitis 
has developed, but after re-infection has occurred immediately after reperfusion, with high 
HCV RNA levels (55). Pre-emptive therapy may be more effective than treatment started only 
after HCV recurrence histological and biochemically has occurred, optimally within one month 
post-LT. However, early post-transplant recipients have higher doses of immunosuppressive 
drugs and the tolerability to peg-IFN and RBV treatment is limited. The risk of acute cellular 
rejection is higher during this period, and will increase with IFN (115-117), and the SVR rates 
are found to be low, only 8-20%. Hence, pre-emptive treatment with peg-IFN and RBV is 
applicable in few transplant recipients.  
5.2.4   Treatment of established recurrent HCV 
Treatment with Peg-IFN and RBV for recurrent HCV infection was until recently the only 
treatment regimen available. SVR and prevention of disease progression was the main goals. 
SVR rates varied between 20-45% depending on genotype, thus in HCV genotype 1 only 15-
30% achieved SVR as reviewed 2008 by Berenguer et al in (110).  
From 2008 and onwards, the main strategy has been to start therapy earlier, when the initial 
signs of histological recurrence are evident in a liver biopsy, due to the low SVR rate in 
transplant patients with advanced fibrosis/cirrhosis (109, 118, 119). In a study from 2012, SVR 
according to fibrosis stage ranged from 52% in patients with mild fibrosis (F1-F2) to 35.5% in 
patients with advanced fibrosis/cirrhosis (F3-F4) (118). 
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5.3   TREATMENT IN PATIENTS WITH FIBROSING CHOLESTATIC 
HEPATITIS (FCH) 
Antiviral treatment with Peg-IFN and RBV in recipients with FCH, is associated with low SVR 
rates, risk for ACR, and serious side-effects. In a study from 2006, 10 patients with FCH treated 
with peg-IFN and RBV achieved an SVR rate of 20 % (120). Five out of 10 patients achieved 
biochemical response, but remained HCV RNA positive after 48 weeks of treatment, 3 died 
with liver failure, and one due to acute rejection, high-lighting the difficulties faced when 
treating FCH. 
5.4   ADHERENCE TO TREATMENT 
Adherence to antiviral therapy with Peg-IFN and RBV is of great importance since it enhances 
SVR in both transplant and non-transplant patients (43, 44, 108, 121). A good adherence to 
antiviral therapy is defined as patients who receive 80% or more of the total Peg-IFN dose, and 
80% or more of the total RBV dose, and have completed 80% or more of the expected duration 
of therapy. In transplant patients, the tolerance to antiviral treatment is low with frequent side-
effects, primarily RBV induced anemia, which leads to frequent dose reductions (70%), and 
treatment discontinuations (30%) (122). 
5.5   SIDE EFFECTS IN ANTIVIRAL TREATMENT WITH PEG-IFN AND 
RBV 
5.5.1   Hematological complications 
Hematological side-effects are largely attributable to IFN-related bone-marrow suppression 
affecting all three cell lines, and RBV-related, dose-dependent, hemolytic anemia (123, 124). In 
non-transplant patients, the hematological side-effects induced by the antiviral treatment also 
cause dose-reductions (32, 125). The hematological side-effects, however, are more pronounced 
in transplant patients. 
5.5.2   Ribavirin 
Ribavirin (RBV) is a purin nucleoside analogue with antiviral activity against DNA and RNA 
viruses (126). RBV mono-therapy has effect on ALT levels but does only reduce HCV RNA 
levels slightly (28) (124).  
RBV induces a dose-dependent hemolytic anemia (31, 124). RBV is eliminated via renal 
excretion, which often is impaired in transplant patients, making them vulnerable to the 
hematological side-effects of RBV. The concentration of RBV correlates with the SVR rate, and 
concentrations needed for a sufficient viral response will thus cause anemia (127). The 
therapeutic target concentration is estimated to 10-15 µmol/L to reach an SVR rate of 80% in 
non-transplant HCV genotype-1 patients (128). 
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5.5.3   Interferon 
Interferon (IFN) is a potent immune modulator, affecting both the innate and the adaptive 
immune system (129). During antiviral treatment it is associated with a rapid suppression of 
hematopoiesis and causes leucopenia and thrombocytopenia (123). 
5.6   MANAGEMENT OF HEMATOLOGICAL SIDE-EFFECTS 
5.6.1   Anemia 
The most notable adverse effect of RBV therapy is hemolytic anemia, and most patients 
receiving antiviral treatment with Peg-IFN and RBV experience a decrease in their hemoglobin 
levels, associated with fatigue, reduced exercise tolerance and decreased quality of life. To 
counteract the hematological side-effects of antiviral treatment, and increase adherence to the 
treatment course, erythropoietin (EPO) has been utilized. EPO in non-transplanted patients has 
increased the number of patients able to maintain their RBV dose throughout the treatment 
course (130, 131). 
5.6.2   Leucopenia 
A decrease in WBC counts, due to bone marrow suppression induced by Peg-IFN, is seen 
during treatment of HCV patients (123, 125). This has been discussed as a potential risk for 
bacterial infections (132), and recently, Peg-IFN and RBV in combination with 1st generation 
PIs, showed an increased frequency of serious bacterial infections (133). Filgastrim, a 
recombinant human granulocyte colony-stimulating factor (G-CSF), is used in several studies to 
counteract neutropenia, reviewed in 2008 (110). In most cases, however, neutropenia can be 
managed effectively with recommended dose modifications of Peg-IFN (134).  
5.6.3   Thrombocytopenia 
Thrombocytopenia is associated with advanced cirrhosis, with an insufficient hepatic 
production of thrombopoietin (TPO) and increased sequestration of platelets in the spleen. 
Patients with advanced cirrhosis have a higher risk of developing thrombocytopenia during 
treatment with IFN, and IFN dose modifications are frequent in such patients (123, 134).  
5.6.4   Other side-effects 
The most common other IFN induced side-effects are fever, flu-like symptoms, headache and 
depression (120). Other side-effects noted are thyroid disorders, ACR, liver failure and 
psychosis (110). 
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5.6.5   Rejection 
The overall incidence of ACR in HCV transplanted patients varies between 30-50% (135). ACR 
is a rare but serious IFN induced complication during IFN based treatment for recurrent 
hepatitis C after liver transplantation. The reported incidence is ranging from 0 to 35% (129). 
5.7   PREDICTORS OF RESPONSE 
Predictors of response to peg-IFN and RBV treatment in immune-competent patients have been 
evaluated (41, 42). In transplanted patients, the recipient, donor and on-treatment factors have 
been evaluated in several treatment studies and reviewed (110). EVR at 12 weeks was the 
strongest on-treatment predictor of response in transplant patients. Monitoring of HCV RNA 
levels is therefore important for identification of patients who should discontinue treatment. 
Other important host-related predictors of treatment response are fibrosis pre-treatment, where 
treatment initiated at earlier stages of fibrosis predicts higher SVR rates (118). Concerning HCV 
genotype, higher SVR rates are associated with genotype 2 and 3. (136, 137, 138, 139). The 
IL28B genotype in the donor and recipient has a substantial impact on the outcome of peg-IFN 
and RBV treatment post-transplant (94, 98, 140). Higher SVR rates are noted in patients with 
the favorable IL28B CC genotype, the highest when the most favorable genotype CC is present 
in both the donor and recipient. 
5.8   LONG-TERM BENEFITS OF TREATMENT   
5.8.1   Treatment and fibrosis progression 
The response to INF-based therapies is associated with improved outcome including improved 
histology with diminishing fibrosis. However, due to small sample size, and different scoring 
systems used, the association has not been as obvious as that seen in immuno competent 
patients (141). Treatment has often been initiated 3 months or more after the liver biopsy was 
performed, allowing further progression of fibrosis to occur before treatment is commenced, 
contributing to difficulties to show histological benefit from antiviral treatment. In studies with 
follow-up biopsies 3-5 years after treatment, the benefit of antiviral treatment on fibrosis 
progression seems to be more evident. In one study, the rate of fibrosis progression diminished 
after antiviral treatment, and progression of fibrosis seemed to be prevented when SVR was 
achieved (142). Another study showed that fibrosis stabilization and improvement became 
evident first in the biopsy performed at least 12 months post-treatment, with histological 
improvement in 92% in patients with SVR and only in 41% in non-responders to treatment 
(118).  
5.8.2   Treatment and survival  
Since SVR to antiviral treatment is associated with regression of fibrosis, treatment also plays a 
key role in the prevention of hepatitis C-related graft failure and for survival. Significantly 
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lower mortality was noted in recipients who achieved SVR (137). In another study, the survival 
was significantly higher in treated recipients than in matched untreated controls 7 years after 
LT, and patients with mild fibrosis had a more pronounced survival benefit from treatment 
(118). There is, thus, a significant improvement in survival among patients who achieve SVR, 
and patients with mild disease benefit most from antiviral therapy. Hence, antiviral treatment 
should be offered early in recipients with recurrent hepatitis C after LT. 
5.9   RE-TREATMENT  
Liver transplant patients with HCV recurrence who are non-responders to antiviral treatment 
will ultimately need a new liver transplant when end stage liver disease is reached. Data 
regarding re-treatment are scarce but in one study, SVR was achieved in 35% of the 79 retreated 
patients who were prior non-responders with cirrhosis present in 37% (143). Full-dose RBV 
was used with EPO-support. EVR was the strongest predictor of SVR followed by age, disease 
severity, and adherence. Thus, treatment response with re-treatment can be predicted by the 
same factors as response in naïve LT recipients, and SVR can be achieved in 1 of 3 patients, 
provided growth factors are given and the patients stay adherent to treatment. 
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6 NEW TREATMENT STRATEGIES 
6.1   ANTIVIRAL TREATMENT WITH PEG-IFN AND RBV IN   
COMBINATION WITH 1ST GENERATION PROTEASE INHIBITORS 
(PIs) 
There have been significant changes in the management of non-transplant patients with HCV 
genotype 1 infections with the approval of two HCV NS3/4A serine protease inhibitors (PIs), 
telaprevir (TVP) and boceprevir (BOC). The addition of these 1st generation PIs to the previous 
standard of care with Peg-IFN and RBV, increased SVR rates to approximately 75% in HCV 
genotype 1 (144-146). 
In transplant patients however, hematological side-effects, infections, and drug-drug 
interactions with CNIs, made this treatment dangerous, and it did not gain broad acceptance 
(133, 147). Triple therapy with 1st generation PIs has now been abandoned.  
6.2   TREATMENT WITH NEW DIRECT ACTING ANTIVIRALS (DAAS)  
With the introduction of new DAAs, patients on the transplant waiting list with HCV cirrhosis 
can be treated more safely and with higher SVR rates. Pre-transplant Sofosbuvir and RBV have 
been given to patients with chronic HCV infection with compensated cirrhosis (104). At time of 
transplantation, 93% were HCV RNA negative and 64% were still HCV RNA negative 12 
weeks post-transplant. Among the 25 patients who had been HCV RNA negative 4 weeks or 
more pre-transplant, there was only one relapse (4%).  
Also, after transplantation, in recipients with HCV recurrence, the treatment possibilities are 
rapidly changing and IFN-free regimens are introduced which carries improved SVR rates.  
Sofosbuvir in combination with RBV has been given to patients with HCV relapse during 24 
weeks to patients with severe fibrosis (F3-4). The majority became HCV RNA negative already 
at treatment week 4 and continued to be so at end of treatment. Finally, the preliminary report 
stated that 77% achieved SVR12, indicating cure (105). No interaction with CNIs was noted 
and the treatment was well tolerated. Combination treatment with drugs from 2 DAA classes 
has been used successfully for treatment of FCH in a case report (148). 
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7 AIMS 
The overall aim was to study the natural course of hepatitis C recurrence after liver 
transplantation, the influence of antiviral therapy with Peg-IFN and RBV and IL28B 
polymorphism in the recipient and donor on the long-term outcome. 
7.1   SPECIFIC AIMS 
1 To develop an optimal RBV dosing schedule in liver transplant recipients.  
2 To evaluate a concentration guided Ribavirin dosing scheme in liver transplant 
recipients.  
3 To study the influence of treatment adherence and compliance on the SVR rate. 
4 To evaluate the utility for prediction of fibrosis outcome of protocolled 6 and 12 
months liver biopsies after liver transplantation. 
5 To study the impact of fibrosis stage prior to treatment, IL8B SNP (rs12979860) 
in donor and recipient, and host factors on treatment outcome. 
6 To evaluate the progression of fibrosis in the liver graft after HCV recurrence 
according to treatment outcome and IL28 gene polymorphism. 
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8   MATERIALS AND METHODS 
8.1   STUDY PARTICIPANTS 
In paper I, II and IV all patients were liver transplanted at Karolinska University Hospital, 
Huddinge, due to end-stage liver disease caused by HCV with or without HCC. Data on liver 
transplant recipients and their donors are available in InfCare Hepatitis, Equator and local data 
bases at Karolinska University Hospital, described in detail below. In paper III, a Nordic 
Multicenter Study on treatment of recurrent hepatitis C, patients were recruited from each 
participating center. 
 
 
 Figure 4: Overwiev of study participants in paper I - IV 
8.1.1   Paper I 
In a pilot study on concentration guided RBV-dosing with EPO support, 21 patients liver 
transplanted at Karolinska University Hospital, Huddinge due end-stage liver disease caused by 
HCV with or without HCC from 1999 to 2008 where included. The majority of patients where 
Caucasian. Eleven patients had HCV genotype 1 or 4 and 10 patients had HCV genotype 2 or 3. 
Patient characteristics are depicted in Table1 in paper I.  
Twenty of 21 were also included in Paper II 
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8.1.2   Paper II 
The influence of IL28B polymorphism on the natural course and treatment outcome in 54 liver 
transplant recipients with recurrent HCV, was studied. All the patients were transplanted at 
Karolinska University Hospital Huddinge between 1997-2010, due to end-stage liver disease 
caused by HCV, with or without HCC, and all were treated with Peg-IFN and RBV post-
transplant, during 2001 to 2011. Pre-treatment with EPO and concentration-guided RBV dose 
was used, in 38/54 according to the protocol described in paper I. All 54 recipients were 
analyzed for IL28B genotype and 45 of their donors. The majority of the recipients were 
Caucasian, and 35 had HCV genotype 1 or 4 and 19 had genotype 2 or 3. Patient characteristics 
are depicted in Table I in study II. 
8.1.3   Paper III  
In a Nordic Multicenter Study on concentration-guided RBV-dosing with EPO support, 54 
patients from the four participating centers were included; 29 patients from Karolinska 
University Hospital, 8 from Sahlgrenska University Hospital, 9 from Malmö University 
Hospital, and 8 from Akers Rikshospital, Oslo. All patients were transplanted due to end-stage 
liver disease caused by HCV, with or without HCC. 36 patients had HCV genotype 1 and 4 and 
18 had HCV genotype 2 or 3. All patients were pre-treated with EPO, starting 2 weeks prior to 
the RBV and Peg-IFN treatment was initiated, and continued throughout the entire treatment. 
The formula used for calculating the RBV-dose is described in detail in paper I and III. Patient 
characteristics are depicted in Table 1 in paper III. 
18 of these recipients were also included in paper II. 
8.1.4   Paper IV 
In this study, we evaluated the utility of protocolled liver biopsies performed 6 and 12 months 
post-transplant. We included 46 patients who had a liver transplant at Karolinska University 
Hospital, Huddinge due to end-stage liver disease, caused by HCV with or without HCC during 
2008 to 2011. The majority of patients were Caucasians, and 36 had HCV genotype 1 or 4 and 
18 genotype 2 or 3. Patient characteristics are depicted in table 1 in study IV.  
7 of these recipients were also included in paper II. 
8.2   METHODS 
8.2.1   InfCare Hepatitis  
All patients with hepatitis C monitored and treated at the Department of Infectious Diseases at 
Karolinska University Hospital are registered in the database InfCare Hepatitis. Demographics, 
virology, biochemical testing, histological findings, data on treatment regimen, and response to 
treatment were extracted in all our study patients from this data base. 
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8.2.2   Eqvator 
All liver transplanted patients at the Department of Transplant Surgery at Karolinska University 
Hospital are registered in the database Eqvator. Data from donor, recipient, surgery, rejection 
episodes, immunosuppressive drugs, graft and patient survival was extracted. 
8.2.3   Virological methods 
HCV genotyping was performed by a line probe assay (Inno-LiPA HCV 2, Innogenetics NV, 
Gent, Belgium) or by an in-house method. 
Hepatitis C virus RNA levels (HCV RNA) were measured at time of transplantation and during 
routine follow-up at the Department of Transplant Surgery, Karolinska University Hospital and 
at the Department of Infectious Diseases, Karolinska University Hospital, using the Roche 
TaqMan test with a sensitivity of 15 IU/mL. In the treatment studies (paper I and III), HCV 
RNA was measured at baseline, at 4 weeks, 12 weeks, at EOT, and during follow-up 6 months 
after stopping treatment. 
8.2.4   Antiviral treatment  
All treated patients in paper I-IV received Peg-IFN alfa 2a, 180 µg in patients with HCV 
genotype 1 and 4 and 135 µg in HCV genotype 2 or 3.  
RBV formula and dose 
All patients in paper I and III were pre-treated with EPO, starting 2 weeks prior RBV and Peg-
IFN treatment was initiated, and continued throughout the entire treatment The RBV dose was 
calculated with a formula taking body weight and renal function into account, initially 
developed and studied in patients with hepatitis C and renal insufficiency (149): 
RBV dose = 0.244 x Ctarget x T x (0.122 x Clcreat + 0.0414 x body weight) 
Ctarget set to 10 µmol/L and T set to dosage intervall 12 hours 
0.244 is a scale factor to convert RBV dose from µmol to mg. 
8.2.5   RBV concentration 
The target RBV plasma concentration was set to 10 µmol/L, and was analyzed at week 4 and 
week 12 during the treatment. 
8.2.6   Treatment outcome definitions 
Rapid viral response was defined as a negative HCV RNA test at week 4, EVR and complete 
early viral response (cEVR) as a 2 log10 drop in HCV RNA levels and a negative HCV RNA 
test, respectively, 12 weeks after starting treatment. Patients who did not achieve EVR stopped 
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treatment at week 12. End-of-treatment viral response (ETR) was defined as negative HCV 
RNA when treatment was stopped, and SVR as negative HCV RNA at treatment stop and after 
24 weeks of follow-up. 
8.2.7   Adherence to treatment  
Adherence was defined as complete if treatment in patients with genotype 2 and 3 was carried 
on throughout the 24 weeks, and for genotype 1 and 4 throughout the 48 weeks. Adherence to 
treatment was also defined as complete if the treatment was withdrawn at week 12 owing to 
non-response, and at week 24 if HCV RNA had not become negative. 
8.2.8   Hematological parameters 
All hematological parameters were analyzed at accredited laboratories at Karolinska University 
Hospital. 
8.2.9   DNA extraction and IL28B genotyping 
Genomic DNA was extracted from peripheral blood or from spleen. The DNA from spleen was 
extracted in NucliSens, EasyMAG, Biomérieux. The DNA samples were genotyped for IL28B 
rs12979860 polymorphism with TaqMan SNP genotyping assay (Applied Biosystems Inc, 
Foster City, CA,USA), using the ABI 7500 Fast equipment. All TaqMan probes and primers 
were designed and synthesised by Applied Biosystems Inc. Automated allele calling was 
performed using SDS software from Applied Biosystems. The primers and probes used were: 
rs12979860 Forward primer: 5´GCCTGTCGTGTACTGAACCA3´, Reverse primer: 
5´GCGCGGAGTGCAATTCAAC3´, Vic probe: 5´TGGTTCGCGCCTTC3´, Fam probe: 
5´CTGGTTCACGCCTTC3´. Human genomic DNA was purified from 5 x106 spleen cells 
according to the manufacturer’s instructions using the QIAamp DNA Mini kit (Qiagen, Tokyo, 
Japan), except for one change in the elution step, elution was done using 100 microliter elution-
buffer instead of 200 microliter. The result is presented as CC, C/T or TT genotype.  
8.2.10   Allograft histology  
All liver biopsies were fixed in 4% formaline in a phosphate buffer, dehydrated and embedded 
in paraffin. Tissue sections, 2-3 μm thick, were cut on a microtome and stained with 
hematoxylin/eosin (HE) and Sirius staining, 8 and 4 section levels respectively. The biopsy 
material was defined as representative if the number of portal zones were > 8. Inflammation 
was graded 1-4 (A 1-4) in HE staining and the fibrosis staged 1-4 (F 1-4) according to Ludwig 
and Batts (25). HCV recurrence was confirmed when a liver biopsy showed findings consistent 
with histological relapse and F 1 or more, provided HCV RNA was detectable in serum. The 
fibrosis was defined as mild when the fibrosis stage was F ≤ 2 and severe when it was F ≥3. 
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8.2.11   Liver stiffness measurement (LSM) by FibroScan 
After 2009, liver elasticity by FibroScan, was performed routinely in patients with a biopsy 
showing HCV recurrence, and also during follow-up after antiviral treatment. The liver 
elasticity was measured in kPa, and the fibrosis staged as F1 – F4 according to Castera et al 
(26). 8.7 kPa was used as cut-off where kPa ≤ 8.7 correlates to F≤1 and kPa > 8.7 to F ≥ 2. (83). 
8.2.12   Statistics 
The Chi-Square test was used for categorical variables and the Wilcoxon Rank Sum test for 
continuous variables in paper I-IV. A P value < 0.05 was considered statistically significant. All 
data were analysed using JMP software version 9.0.0. 
In paper II we performed an univariate analysis on factors associated with SVR. We included 
recipient and donor age, gender, HCV genotype, IL28B gene polymorphism, in both donor and 
recipient, baseline viral load, time from LT to treatment and fibrosis pre-treatment. The factors 
found to be significantly associated with SVR, HCV genotype and fibrosis pre-treatment, were 
included in a stepwise Cox regression model. In paper III we performed an univariate analysis 
on factors associated with SVR. We included age, gender, HCV genotype, IL28B gene 
polymorfism, fibrosis pre-treatment, and mean RBV concentration at week 4 and 12. The 
factors found to be significantly associated with SVR, HCV genotype, IL28B genotype and 
fibrosis pre-treatment, were included in a stepwise Cox regression model. 
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9 RESULTS AND DISCUSSION 
9.1   Paper I: PILOT STUDY ON CONCENTRATION GUIDED RBV 
DOSING WITH EPO SUPPORT 
21 HCV liver transplant recipients received Darbepoetin with start 2 weeks prior to treatment 
start and continued during the entire antiviral therapy. 
9.1.1   Adherence and tolerance to treatment 
In HCV genotype 1, 82% completed treatment and 90% in HCV genotype non-1. Thus, a 
majority of our patients stayed adherent to a full treatment course, an improvement compared to 
other studies with fixed RBV dose and without EPO support (109, 150). Only one patient ended 
treatment early due to anaemia. The majority of patients had reasonable fall in hemoglobin 
levels (mean hemoglobin fall, 20–25 g/L). To achieve this, however, dose escalation of 
Darbepoetin to 150 µg weekly was required in 40% of the patients. No serious adverse events 
occurred and no rejection episode was noted during treatment and follow-up. Thus, treatment 
with Peg-IFN and concentration guided RBV with EPO support can be considered safe, and for 
HCV genotype non-1patients a cost-saving alternative compared to treatment with new DAA 
combinations. 
9.1.2   RBV concentration 
The RBV concentration of 10 µmol/L is generally correlated with favorable SVR rates in non-
transplanted and haemodialysis patients (127, 151).This concentration was possible to achieve 
in the absolute majority of our patients, but only when we used pre-treatment with Darbepoetin. 
Dose adjustment of RBV was made in 48% of our patients, underlining the necessity of 
monitoring the RBV concentration during treatment. 
 
 
Table 1:  Ribavirin concentrations week 4 and 12 according to HCV genotype 1/4 or 2/3 
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9.1.3   Treatment response 
ETR was achieved in 36% and 80% in HCV recipients with genotype 1 and non-1 respectively 
(p<0.05), and the corresponding figures for SVR was 18% versus 60% (p=<0.05). Two patients 
in each group relapsed after treatment. The overall SVR rate was thus not impressive. If 
treatment is initiated at earlier stages of fibrosis, the SVR rate would probably be higher (118). 
In accordance with these findings, patients with low-grade fibrosis (F 1-2) achieved SVR in 50 
%, where no patient with advanced fibrosis (F 3-4) did (P < 0.05). If we excluded patients with 
advanced fibrosis, patients with HCV genotype 1 and non-1 achieved SVR in 29% versus 67%. 
Thus, almost two thirds of patients with the favorable combination of low grade fibrosis and 
HCV genotype non-1 achieved SVR, the same figure as seen in non-transplanted patients (32, 
33, 44). 
 
 
  Figure 5: Treatment response according to HCV genotype and fibrosis stage 
 
9.2   PAPER II: THE INFLUENCE OF IL28B GENE POLYMORFISM IN 
RECIPIENT AND DONOR ON FIBROSIS PROGRESSION AND 
TREATMENT RESPONSE 
We analyzed the IL28B genotype rs12979860 in 54 patients, all transplanted due to HCV, and 
in 45 of their donors.  
9.2.1   Distribution of IL28B genotype 
Among the 54 recipients, 12 had IL28B CC and 42 IL28B non-CC. In the 45 donors the IL28B 
CC genotype was more frequent, 30 versus 15 with IL28B CC and non-CC respectively. The 
difference in distribution was significant both in recipient and donor. This is seen also in 
previous studies (94, 97), and an explanation for this could be that the favorable genotype CC is 
associated with a higher spontaneous clearance rate, and that more HCV patients with genotype 
CT and TT will develop chronic HCV and cirrhosis, eventually leading to end-stage liver 
disease and liver transplantation (21). Similarly, as in non-transplanted patients, the IL28B CC 
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genotype in transplant recipients is associated with higher SVR rates after SOC treatment than 
the non-CC genotype (94, 97, 98). Hence, non-CC recipients are more likely to be prior non-
responders to treatment with Peg-IFN and RBV, increasing the proportion even further of non-
CC patients among liver transplant recipients.  
9.2.2   Treatment response according to HCV genotype 
The SVR rate in HCV genotype 1 versus non-1 was 9/35 (26%) and13/19 (68%) (p=0.002), in 
agreement with earlier findings in IFN-based treatment regimens (110, 119). 
9.2.3   Treatment response according to IL28B genotype 
The SVR rate according to IL28B genotype was 58% for CC and for recipients with IL28B CC, 
36% (p=0.16). The corresponding figures according to IL28B genotype in the donor was 43% 
versus 40%, respectively (p=0.83). Although not significant, a trend towards a more favorable 
treatment outcome was noted in both recipient and donor with IL28B CC genotype.   
The effect on SVR rate in recurrent hepatitis C after liver transplantation, associated with the 
recipient IL28B genotype, has been shown earlier and was reviewed in 2012 (152). The 
influence of IL28B donor genotype alone, is not as clear. The combination of IL28B CC both in 
the donor and in the recipient has been found to be the most favorable (95, 152). 
When we combined HCV genotype non-1 and IL28B CC in the recipient, SVR was achieved in 
71% achieved SVR versus only 23% in the recipients with HCV genotype 1 and IL28B non-CC 
(p= 0.02).  
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Figure 6: Treatment response according to HCV genotype 1 and non-1, and according to HCV 
genotype and IL28B genotype combined 
9.2.4   Treatment response according to fibrosis stage pre-treatment 
SVR in recipients with in mild fibrosis (F 1-2) and advanced fibrosis (F 3-4) at baseline, was 
61% and 27% respectively, indicating the importance of treating patients at an early fibrosis 
stage of recurrent HCV, to increase the possibility to achieve SVR. (118, 119). 
9.2.5   Fibrosis progression post-transplant according to IL28B 
genotype 
Recipients with IL28 CC tended to have less advanced fibrosis prior to treatment initiation. 
Thus, mild fibrosis was seen in 64% of recipients with IL28B CC, versus 38% of recipients 
with IL28B non-CC, a non-significant difference, p = 0.13. Although earlier finding are not 
uniform, the IL28B CC genotype seems to be associated with a slower fibrosis progression 
post-LT (94). At follow-up after treatment, significantly more of our recipients with CC had 
mild fibrosis than recipients with non-CC, 75% versus 32%, respectively. All recipients with 
SVR who had IL28B CC, had mild fibrosis. 
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9.3   Paper III: NORDIC MULTICENTER STUDY ON TREATMENT FOR 
HCV RELAPSE AFTER LIVER TRANSPLANTATION 
54 liver transplant patients from four Nordic centers were recruited. All received Darbepoetin 
with start 2 weeks prior to treatment initiation and throughout the antiviral therapy. RBV was 
given concentration guided with Peg-IFN. 
9.3.1   Adherence and tolerance to treatment 
Two patients with HCV genotype 1 withdrew from treatment prematurely, one at week 1 due to 
rash and pruritus, and one at week 4 due to myocardial infarction. Among HCV genotype non-1 
infected recipients, one stopped treatment early due to severe cholangitis at week 7. The mean 
drop in hemoglobin level in the recipient was 37 g/L (range 0-87). The nadir hemoglobin level 
occurred at week 22 (range 4-56). The Darbepoetin dose had to be adjusted in 52% of the 
patients. It was raised due to anemia in 88%, and tapered due to high hemoglobin levels in 12%. 
2 patients needed blood transfusions. Thus, both adherence and tolerance to the treatment 
course was excellent, as seen in paper I (119). To achieve these figures however, frequent 
monitoring and dose adjustments were necessary. 
9.3.2   RBV dose and concentration 
The RBV dose needed to achieve an intended serum concentration is highly individual and 
dependent on kidney function. By using the formula from paper I, developed for antiviral 
treatment with Peg-IFN and RBV in patients with kidney failure (127, 151), it was possible to 
individualize the dose also in liver transplant patients, who often suffers from impaired renal 
function, due to co-morbidities and immunosuppression with CNI (49). The mean RBV dose at 
treatment start was 800 mg (range 400-1400 mg). Dose adjustments were done dependent on 
the RBV concentrations noted at week 4 and week 12, or due to anemia, in 78% of the patients.  
The intended serum RBV concentration of 10 µmol/L, was achieved in a majority of the 
patients. The mean serum RBV concentration at week 4 was 7.7 µmol/L (range 3.1-15.9), and at 
week 12 11.2 µmol/L (5.3-21.6), with no significant difference between HCV genotype 1 and 
non-1. Hence, the RBV dosing formula worked well in this study. Since new direct antiviral 
drugs (DAAs), in particular Sofosbuvir, have recently become available for treatment of HCV 
relapse in liver transplant patients, treatment options are changing rapidly. Presently, however, 
RBV is still used. Thus, an optimized RBV dose will continue to be of importance, also when 
Sofosbuvir is used in combination with RBV, a combination that has offered very promising 
results, when used both prior to and after LT (104, 105). 
 
. 
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9.3.3   Virological response according to fibrosis stage pre-
treatment, HCV genotype and IL28B genotype  
Before 2008 antiviral therapy was not initiated at early stages of HCV recurrence. This led to 
poor SVR rates since treatment response is generally lower in patients with advanced 
fibrosis/cirrhosis (118, 119). In our study, 50% of the patients had mild (F 1-2) fibrosis at 
treatment start. Patients with mild (F 1-2) and advanced fibrosis (F 3-4), achieved SVR in 56%, 
and 26% respectively, p = 0.025.  
As discussed earlier in paper II, the HCV genotype and the IL28B genotype have a profound 
influence on the treatment response in liver transplant patients (153). SVR was thus achieved in 
recipients with HCV genotype 1 in 22%, and with HCV genotype 2 and 3 in 78%. In patients 
with IL28B CC versus non-CC, SVR was achieved in 73% and 33% respectively. 
9.3.4   Univariate and multivariate analysis of factors associated with 
SVR 
Factors associated with SVR in univariate analysis were HCV genotype, IL28B gene 
polymorphism and fibrosis pre-treatment. Only HCV genotype (p=0.0003) and IL28B gene 
polymorphism (p=0.007) were significantly associated with SVR in the multivariate analysis, 
whereas fibrosis pre-treatment (p=0.06) did not reach full statistical significance. Our univariate 
analysis and earlier findings, however, have shown that less advanced baseline fibrosis stage 
predicts a better treatment response (118). 
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Variable    Univariate  
 
Age over (n=28)/under (n=23) mean 56  p = 0.08   
Sex M (n=40)/F (n=11)   p = 0.61   
HCV gt 1 (n=34)/gt non-1 (17)  p = <0.0001*  
IL28B CC (n=11)/non-CC (40)  p = 0.025* 
F1-2 (n=26)/F3-4 (n=25)   p = 0.031* 
F1-3 (n=40)/Cirrhosis (n=11)  p = 0.22   
RBV under (n=27)/over (n=24) mean 7.7µmol/L p = 0.06   
RBV under (n=27)/over (n=22) mean 11.2 µmol/L p = 0.28 
     
Variable    Multivariate 
 
HCV gt 1 (n=34)/gt non-1 (17)  p=0.0003* 
IL28B CC (n=11)/non-CC (40)  p=0.007* 
F1-2 (n=26)/F3-4 (n=25)   p=0.06 
 
Figure 7: Univariate and multivariate analysis of baseline factors associated with favorable 
treatment outcome 
HCV genotype and IL28B gene polymorphism in the recipient were found to be the most 
important baseline predictors of treatment response to Peg-IFN and RBV in patients with HCV 
relapse after transplantation. When HCV genotype and IL28B gene polymorphism were 
combined for prediction of response, the highest SVR rate was found in recipients with HCV 
genotype 2 and 3 and IL28B CC, all three patients achieved SVR, as earlier noted by us and 
others (94, 153). However, the overall 43% SVR rate with peg-IFN and RBV was not 
impressive. In HCV genotype 2 and 3 patients, 82% achieved SVR whereas only 24% of HCV 
genotype 1 patients did, p < 0.0001. For recipients with HCV genotype 2 and 3, this is 
comparable to SVR rates in non-transplant patients with genotype 2 or 3 infections, and SVR 
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rates in liver transplant patients treated with Sofosbuvir and RBV (33, 105, 154). Since 
treatment with the new DAAs carries a high cost, this regimen can therefore still be used with 
reasonable treatment results in patients with HCV genotype 2 and 3. For HCV genotype 1 
infected recipients, however, this treatment regimen is suboptimal and should be replaced with 
DAA combinations, including Sofosbuvir, in combination with Daclatasvir or Simeprevir (148). 
9.4   Paper IV: EVALUATION OF EARLY BIOPSY 6 AND 12 MONTHS 
POST-TRANSPLANT  
46 patients transplanted due to HCV, who underwent protocolled liver biopsies 6 and 12 months 
post-LT, were studied. Eleven recipients who were negative for HCV RNA, but anti-HCV 
positive post-LT, served as a control group.  
9.4.1   Histological recurrence at 6 and 12 months post-transplant 
Histological recurrence with fibrosis stage ≥ F1was noted in 56% at 6 months post-LT, the 
majority (18/19) with mild fibrosis (F1-2). It is thus possible to detect HCV recurrence early 
post-transplant, supporting the strategy to perform protocolled biopsies already 6 months post-
transplant. When divided into slow (F0-F1) and rapid (F2-F4) fibrosers at 6 months post-LT, 
76% recipients were slow and 24% rapid fibrosers. IL28B CC was more frequently noted in 
patients with rapid fibrosis (p=0.05)  
The number of patients with histological evidence of HCV recurrence increased to 82% at 12 
months post-LT, where 89% had mild fibrosis (F 1-2). At this time point 44% of the recipients 
were slow fibrosers ( F≤1 ) and 56% were rapid fibrosers with F ≥ 2.  
9.4.2   Factors associated with rapid HCV recurrence 
It has previously been shown that treatment of ACR with steroid boluses or anti-lymphocytic 
agents, will lead to an enhanced viral replication, higher HCV RNA levels, and an increased 
fibrosis progression (77, 155). This is in accordance with our findings where the 3 recipients 
with severe fibrosis progression at 12 months post-LT all had suffered from ACR. 
The IL28B CC genotype was associated with rapid fibrosis progression also at 12 months post-
LT, p=0.01. Earlier findings on fibrosis progression and IL28B CC have not yielded uniform 
results. Hence, some found a more pronounced inflammatory activity, in IL28B CC recipients, 
leading to a rapid fibrosis progression (95). 
9.4.3   Liver transplant recipients with slow fibrosis progression 
Some liver transplant recipients with HCV recurrence will have a slow fibrosis progression. In 
the 26 recipients with slow fibrosis progression at 6 months post-LT, 50% had F0-F1 also in the 
12 months biopsy. This is an interesting finding, since this subgroup of patients may not need 
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antiviral treatment, at least not early post-LT. Due to the expected high costs with the new 
DAAs, identifying this group is also important concerning saving of costs.   
9.4.4   Evaluation of fibrosis in the HCV RNA negative control group 
In the HCV RNA negative control group, 18% had fibrosis in the graft at time of 
transplantation. However, none of the eleven recipients showed histological signs of HCV 
recurrence during follow-up. Up till now, IFN-based regimens given pre-transplant have been 
associated with poor SVR rates and a risk of complications (112, 114). With the new DAAs 
however, antiviral treatment pre-transplant, also in cirrhotic patients, has offered promising 
results (105). 
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10 CONCLUSIONS AND FUTURE ASPECTS 
The formula we used for calculating the RBV dose, originally developed for patients with renal 
failure, worked well also in liver transplant patients, where the target concentration of 10 
µmol/L was achieved in the majority of our patients. By using Darbepoetin two weeks prior to 
start of treatment with Peg-IFN and RBV, and continuing throughout the whole treatment 
course, tolerance to treatment was improved, and the regimen enabled the patients to stay 
adherent to a full treatment course. Presently, new DAAs are being evaluated among liver 
transplant patients, where RBV in combination with Sofosbuvir have shown promising results. 
Thus, an optimized RBV dose will continue to be of importance in the treatment of HCV 
recurrence post-transplant. 
IL28B gene polymorphism in liver transplant recipient and donors influences the natural course 
and treatment outcome. Among our recipients, the IL28B CC genotype was associated with a 
better treatment response to Peg-IFN and RBV. Recipients with IL28B CC genotype had less 
advanced fibrosis both pre and post-treatment, and all recipients with IL28B CC who achieved 
SVR had mild fibrosis at follow-up. The combination of IL28B CC and HCV genotype non-1 
yielded the highest SVR rates. Even after the introduction of new DAAs in liver transplant 
patients, HCV genotype and IL28B gene polymorphism will still be baseline factors important 
to determine, although the extent needs to be evaluated. 
In paper I+II+III, all patients were treated with Peg-IFN and RBV and treatment response was 
evaluated. Patients with HCV genotype non-1 and IL28B CC genotype had the highest SVR 
rates, and patients with this favorable combination, treated at early stages of fibrosis (F1-2) had 
SVR rates comparable to treatment results in non-transplant patients. Thus, treatment at earlier 
stages of fibrosis should be offered. 
We evaluated protocolled liver biopsies post-transplant, and already at 6 months after 
transplantation about 50% of the recipients showed histological signs of recurrence with F ≥1. 
The corresponding figures at 12 months were more than 80%. We also identified a group of 
liver transplant recipients with HCV recurrence with  slow (F ≤ 1) fibrosis progression post-
transplant, An early liver biopsy is therefore both useful in identifying patients with rapid 
fibrosis progression in order to offer treatment early, and to monitor patients with slow fibrosis 
progression that might not need antiviral treatment, a cost-saving strategy. 
None of the liver transplant recipients, who were HCV RNA negative at time of transplantation, 
showed histological signs of HCV recurrence during follow-up. Therefore, if possible, antiviral 
treatment should be offered pre-transplant, a strategy which will be both safer and more 
efficient with newer treatment regimens. 
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11 SAMMANFATTNING PÅ SVENSKA 
Hepatit C virus (HCV) infektion efter levertransplantation (LT) leder till en snabbare 
ärrbildning än hos icke transplanterade. 25 % av patienterna utvecklar skrumplever (cirrhos) 
inom 5 år efter LT. Antiviral behandling efter LT med Peg-Interferon (Peg-IFN) och ribavirin 
(RBV) har lägre utläkningsgrad (SVR) än hos icke-transplanterade patienter, delvis beroende på 
ökad frekvens av biverkningar, framförallt anemi. Patienter som inte svarar på behandling (NR) 
löper stor risk för att utveckla skrumplever. 
Syftet med denna avhandling var att studera naturalförlopp och behandlingsutfall hos 
levertransplanterade patienter med återfall av hepatit C. Vi studerade även hur basala 
värdfaktorer påverkar förloppet av hepatit C återfallet, och svaret på antiviral behandling, med 
fokus på HCV genotyp och IL28B polymorfism. 
I det första arbetet utförde vi en pilot-studie på 21 patienter, levertransplanterade på grund av 
hepatit C. Alla förbehandlades med Darbepoetin (EPO) med start 2 veckor före den antivirala 
behandlingen med Peg-IFN och RBV. Syftet var att öka följsamhet och tolerans för den 
antivirala behandlingen. RBV doserades enligt en formel baserad på vikt och njurfunktion, en 
önskad serumkoncentration på 10 µM eftersträvades. Majoriteten av patienterna uppnådde 
målkoncentrationen och 90 % fullföljde den planerade behandlingen. 60 % av HCV genotyp 
non-1 uppnådde SVR, men bara 18 % av de med genotyp 1. 67% av patienterna med mild 
ärrbildning (F1-2) uppnådde SVR. I andra arbetet studerade vi IL28B genpolymorfismens 
betydelse för ärrbildning och behandlingssvar bland 54 LT patienter med hepatit C återfall, som 
alla erhållit antiviral behandling, samt bland 45 av deras donatorer. Patienterna med 
kombinationen Il28B CC och HCV genotyp non-1 uppnådde SVR i 71 % mot endast 23% med 
kombinationen IL28B non-CC och HCV genotyp 1. Patienter med mild ärrbildning (F1-2) 
uppnådde oftare SVR. I tredje arbetet behandlade vi 46 svenska och 8 norska patienter med 
koncentrationsstyrd RBV dos, enligt formeln i arbete 1, i kombination med Peg-IFN. Alla 
förbehandlades med EPO. 94 % fullföljde behandlingen. SVR uppnåddes av patienter med 
HCV genotyp 2/3 i 82 % men endast av 22 % med HCV genotyp 1. Patienter med IL28B CC 
uppnådde SVR i 73 % och patienter med IL28B non-CC i 33 %. Patienter med mild ärrbildning 
(F1-2) uppnådde SVR i 56 % och patienter med avancerad ärrbildning (F3-4) i 26 %. Patienter 
med fördelaktig HCV genotyp och IL28B genotyp visade sig ha en bra möjlighet att läka ut sin 
HCV med denna behandlingsregim, framför allt vid mild ärrbildning. I fjärde arbetet 
utvärderade vi möjligheten att använda leverbiopsi tidigt efter LT för att upptäcka och förutsäga 
ärrbildning vid HCV recidiv. 46 HCV RNA positiva och 11 HCV RNA negativa LT patienter, 
som genomgått leverbiopsi 6 och 12 månader efter LT, studerades. Histologiskt HCV återfall 
sågs hos 56 % av HCV positiva patienter 6 månader efter LT, och hos 82 % efter 12 månader. 
Akut avstötning (ACR) och IL28B genotyp CC var faktorer som korrelerade till en mer uttalad 
ärrbildning. Ingen ärrbildning sågs hos de 11 HCV RNA negativa patienterna. Leverbiopsi efter 
LT kan användas för att upptäcka tidigt HCV återfall så att tidig behandling kan ges 
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